Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAA to conduct pivotal study of Lutate in neuroendocrine tumours

This article was originally published in Clinica

Executive Summary

Advanced Accelerator Applications (AAA) is to begin a pivotal Phase III trial of Lutate, its radiolabelled peptide anticancer compound. The 300-patient multicentre trial will assess Lutate in the treatment of patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Saint Genis Pouilly, France-based AAA has commissioned Pierrel Research International to conduct the study. Lutate is a somatostatine analogue labelled with Lutetium-177. It selectively targets somatostatine receptors, which are overexpressed in tumour cells; the radiation then destroys the cells. Lutate has FDA and EMEA Orphan Drug status, giving it protection from competition for seven years in the US and 10 years in Europe following approval. Sales of the compound could begin in 2015 (www.clinica.co.uk, 6 April 2011).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel